5:30pm (EST)
1. Market Summary
2. Seattle Genetics (SGEN) – Superior Product Leads to Value
3. Earnings
4. Weekly Wrap Portfolio Update
5. Week Ahead
= = = = = = = = = = = = = = =
1. Market Summary
The bulls continued their merry way as they scored another weekly win and pushed the major averages to fresh 2-year highs in the process. The strength (or surprise) came from the Financial sector which gained 2.5% on M&A (merger and acquisition) activity. The Regional banking stocks also joined in and had a solid week as traders looked for bargains and possible takeover targets.
The Dow gained 14 points on Friday, or 0.1%, to finish at 11,573. For the week, the bulls made it 4-in-a-row as the index added 82 points, or 0.7%. The Dow is at its highest levels since August 2008 and finally took out strong resistance at 11,500. Our yearend target for the Dow has been 11,600-11,700 and we have mentioned the possibility of the current momentum carrying the bulls up to 12,000 in 2011. Support has strengthened and is now at 11,350 with backup at 11,200.
The S&P 500 is on a 3-week winning streak although it fell 2 points on Friday, or 0.2%, to settle at 1,256, but is also at a 2-year high. For the week, the index gained 13 points, or 1%, and busted through the 1,245-1,250 area which was strong resistance. Our target has been 1,250 with a possible run up to 1,275 by yearend and 1,300 in 2011 if the rally continues. Support is solid at 1,220-1,200.
The drive-for-five was a success as the Nasdaq continues to push 3-year highs. The index fell 6 points, or 0.2%, on Friday but added 23 points for the week, or 0.9%, and closed at 2,665. We told you the 2,660-2-665 area would be the next level the bulls target and we were watching for a break and close above 2,660 as confirmation. We got it and we are now looking for a run up to 2,700 with a shot at 3,000 in 2011. Support remains strong at 2,600-2,550.
Volume has been light, which is usually the case around the holidays, and 3Q earnings are winding down to a close. As the market edges up towards our upper-end targets, next month could play a huge role in determining market direction as 4Q and yearend results start to roll in.
January is also a pivotal month as far as determining market direction for 2011 according to the January Barometer (JB). This “theory” states that however the S&P 500 trades for the month, so goes the rest of the year. The JB was created in 1972 and carries a .783 win rate, on average, but has registered only 6 “errors” since 1950 for a 90% win rate.
This year, at the end of January 2010, the S&P ended at 1,073 after starting the year at 1,115, for a loss of 3.7%. So, unless the market crumbles, the JB was not a good indicator this year. History can and does repeat itself in some situations concerning the market and stocks but what we found interesting was this was the first time that the JB could be wrong for two straight years. In 2009, the S&P 500 dropped 8.6% in January (from 903 to 825) but ended the year higher by 23.5%.
Is it possible the JB could be wrong for the third straight time this January? It would be hard to believe but something that bears watching.
= = = = = = = = = = = = = = =
2. Seattle Genetics (SGEN) – Superior Product Leads to Value
(please see charts on website)
We always need to find new drugs to treat the nearly endless introductions of new diseases. In cancer, this becomes a bigger challenge. The problem: to kill an infectious cell, other normal cells are also killed in the process. That is where Seattle Genetics (SGEN, $15.73, up $0.43), which makes monoclonal antibodies for cancer. Its unique technology gives it an edge over the competition and larger players. This valuable asset could not only help it to succeed, but could make it an attractive acquisition target.
The company was founded in 1997 and is valued at $1.6 billion. Through it is still in red, Seattle Genetics’ year-over-year revenue growth is 37%. The company has no debt and a clean balance sheet. Plus, as shown in the table below, their total revenue has grown each year. Their total earnings loss shrank each year, too. So, the company does not seem to be in any trouble of running out of cash.
Pipeline
It is important to analyze a drug or Biotech’s pipeline to find future value. Below is the company’s pipeline of drugs, its treatment, and the phases they are in.
|
Brentuximab Vedotin |
Relapsed/refractory Hodgkin lymphoma (HL) |
Pivotal/phase III |
|
Post-transplant HL relapse prevention (AETHERA trial) |
Pivotal/phase III |
|
|
Relapsed/refractory systemic anaplastic large cell lymphoma (sALCL) |
Phase II |
|
|
Retreatment of Hodgkin lymphoma, systemic ALCL |
Phase II |
|
|
Front-line HL (+chemotherapy) |
Phase I |
|
|
Front-line sALCL (+chemotherapy) (planned) |
Phase I |
|
|
SGN-75 |
Non-Hodgkin lymphoma |
Phase I |
|
Renal cell carcinoma |
Phase I |
|
|
ASG-5ME |
Pancreatic cancer |
Phase I |
|
Prostate cancer |
Phase I |
|
|
Dacetuzumab (SGN-40) |
Combination trials for non-Hodgkin lymphoma |
Phase I |
|
Combination trials for multiple myeloma |
Phase I |
|
|
SGN-70 |
Autoimmune diseases |
Phase I |
|
SGN-19A |
CD19+ hematologic malignancies |
Preclinical |
SGN-35 is jointly developed in collaboration with Millennium Pharmaceuticals, the wholly owned subsidiary of Japanese-based Takeda Pharmaceuticals. Under agreement, Seattle Genetics has commercializing rights in the United States and Canada. Millennium has exclusive rights to commercialize the drug in the rest of the world. But Millennium must pay $60 million upfront and double-digit royalties on annual net sales of SGN-35.
In the first quarter of 2011, Seattle Genetics plans to submit a Biologics License Application (BLA) for Brentuximab Vedotin (SGN-35) to the FDA for approval for both relapsed/refractory Hodgkin lymphoma (HL) and relapsed/refractory systemic anaplastic large cell lymphoma (ALCL). The latter has only gone through phase II trials, which could pose a problem in getting FDA approval. However, high performance of the drug in futures trials may overcome this.
The 52nd American Society of Hematology (ASH) Annual Meeting reported that for relapsed/refractory HL, 75% of the 102 patients achieved the primary endpoint of the trial. Out of the 94% of patients who had reductions in tumors, 34% achieved a complete remission. Side effects were mild compared to current chemotherapy and included sensory neuropathy, fatigue, nausea, upper respiratory tract infection, and diarrhea. For ALCL, 86% of the 58 patients achieved the primary endpoint of the trial. Complete remission was 53%, and tumor reductions were 97%. Side effects were also mild and included nausea, peripheral sensory neuropathy, fatigue, fever and diarrhea.
HL, a cancer originating from white blood cells in the immune system, usually affects young adults ages 15–35 and those over 55. The Leukemia & Lymphona Society estimates that there would be 8,490 cases of HL in the U.S. in 2010. Worldwide, there are over 62,000 cases reported annually. The drug, if approved, will be the best product on the market. No current drug has better response rates. Therefore, SGN-35 will very likely capture a large pie of the market. If it grabs 50% of the market, that would be $212.25 million in annual U.S. sales, assuming the price is $50,000. Plus, the royalties will be at least $100,000 for sales outside the U.S. Worldwide sales should top $1.55 billion, assuming it takes 50% of the market and the drug costs $50,000. That makes a total of about $312 million annually. That is a lot for a $1.6 billion company.
But this is just one drug. It has other drugs in its pipeline that could have potential.
Chart
Finally, for short-term moves, it is wise to check the chart for market sentiment. The chart below shows for the year, the stock had a general uptrend. This is positive for a stock, since it gives it momentum and less chance that it will suddenly reverse its uptrend. But notice that the 14-Period MFI (Money Flow Index) appears to be nearing a trough and poise to go back up again. Although there is not great price correlation with the MFI, the price seems to go higher as the MFI goes higher.
Thus, the fundamentals and value of its pipeline and technology make Seattle Genetics (SGEN) appear to be a great buy. And the chart helps to affirm this opinion. Plus at least one drug seems very likely to get approval in the first quarter, bumping up the stock price. On top of that, since its technology seems to be superior to those of its competitors, there is speculation that the company could be an acquisition target. Even if there isn’t a buyout, Seattle Genetics’ pipeline looks strong and poised to deliver a blockbuster drug down the road.
NEW TRADE!!!
We want to take advantage of this situation by buying Seattle Genetics and selling call options. The shares got a nice 3% pop on Friday and the SGEN March 17.50 calls (SGEN110319C00017500, $0.85, up $0.15) jumped over 20%. On Monday, we suggest buying the stock for under $16 and selling 1 March 17.50 call option for every 100 shares you purchase. We will add this trade to our covered call portfolio below.
We are also following Seattle Genetics on our Watch List for our Daily newsletter. As you can see, we are looking at quite a few different ways to play this one.
= = = = = = = = = = = = = = =
3. Earnings
There won’t be any possible earnings trades this week as the only one we have bolded are CALM and IPSU. Cal-Maine reports before the open on Monday so you would have needed to be in calls or puts on Friday to get in on this action. We were following Imperial Sugar at one point earlier this year but the options are thinly traded so we took the stock off our daily Watch List. The company is expected to report a loss, and even if they surprise, we just don’t like the options on IPSU either way.
Monday: Cal-Maine Foods (CALM, $33.82, up $0.02), LiveDeal (LIVE, $6.89, up $0.26), GigaMedia (GIGM, $1.45, flat), Hauppauge Digital (HAUP, $2.66, down $0.05) and Taylor Devices (TAYD, $5.16, down $0.02).
Tuesday: Omega Navigation (ONAV, $1.28, up $0.09).
Wednesday: Brooklyn Federal Bancorp (BFSB, $1.41, down $0.09), First Security Group (FSGI, $0.67, up $0.06) and Onstream Media (ONSM, $0.75, down $0.02).
Thursday: Imperial Sugar (IPSU, $13.90, down $0.04)
Friday: None worth mentioning.
= = = = = = = = = = = = = = =
4. Weekly Wrap Portfolio Update
Patriot Coal (PCX, $18.30, down $0.09) (COVERED CALL)
January 19 call (PCX110122C00019000, $0.76, down $0.08)
Entry Price: $17.80 (12/6/10) sold January 19 call @ $0.95
Exit Target: $20
Return: 9%
Stop Target: None
Action: Patriot Coal opened at $17.51 and shares were at $17.80 around 10am on 12/6/10. The 2011 January 19 call could have been sold for 95 cents. This lowered the cost basis to $16.85.
These options were down to 30 cents but had a strong week after shares got an upgrade. Of course, we hope the options expire worthless so we can sell another call option next month but if you are “called” away the trade will make 13%. This would happen if the stock is trading above $19 by mid-January. Not too shabby for a 6 week trade if it plays out this way.
If shares don’t make $19, we will sell another option to lower our cost basis.
Dendreon (DNDN, $36.86, down $0.52) (COVERED CALL)
February 39 call (DNDN110219C00039000, $1.55, flat)
Entry Price: $41.96 (9/13/10) sold October 45 call @ $1.30, (11/11/10) sold December call @$1.75, (12/20/10) sold February 39 call @ $1.50
Exit Target: $45
Return: -1%
Stop Target: None
Action: Dendreon opened at $41.96 and you could have sold the October 45 call option for $1.30 on 9/13/10. This lowered the cost basis to $40.66.
On 11/11/10 we sold the December 40 call option for $1.75 which lowered our cost basis to $38.91.
On 12/20/10 we sold the February 39 call option for $1.50 which lowered our cost basis to $37.41.
If the stock gets “called away” from us by mid-February the trade will return 5% from when we first profiled it.
We believe Dendreon will be a $60 stock in 2011.
= = = = = = = = = = = = = = =
5. Week Ahead
This week will be extremely light as far as economic news and believe it or not, the market will be open on Friday, New Year’s Eve, despite the fact there will be no economic news or earnings announcements.
Monday is the same deal as not much news will be flowing unless it is from overseas.
Tuesday we get a look at the consumer confidence survey for December as well as the Case-Shiller Index which releases its 20-city home price index for October.
Wednesday’s excitement will be crude inventories while on Thursday the Labor Department will give an update on weekly jobless claims. The Chicago Purchasing Managers’ Index will also be released on Thursday.
For those of you would like more in-depth coverage of the market and options, we suggest you give our daily newsletter a try. We are ending the year on a high note as our subscribers closed another trade last week for a 112% return on top of two other recent trades with returned 170% and 140%, respectively. Overall, our 2010 CLOSED portfolio for our Daily newsletter is positive for the year and has been updated for your review.
]]>

